Glaukos Expands Eye Care Pipeline With New GLK-321 Trial in Demodex Blepharitis

Glaukos Corp. (GKOS) announced an update on their ongoing clinical study.

Glaukos Corp. (GKOS) is running a Phase 2 trial titled “Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis.” The goal is to see if GLK-321 can safely treat Demodex blepharitis, an eye lid disease that lacks many proven options today.

The study is testing GLK-321, an eye drop drug, in several dose levels. It aims to lower signs and symptoms of Demodex blepharitis and could become a new product in Glaukos’ growing eye care pipeline if the data are strong.

The trial is interventional and uses random assignment to compare GLK-321 against a placebo. It is double-masked for patients, doctors, care staff, and outcome assessors, which helps keep results objective and focused on real treatment effects.

This is a parallel-group design, so each participant stays on their assigned treatment arm for the study. The main purpose is treatment, not diagnosis or prevention, and the Phase 2 label means the focus is on early proof of benefit and safety signals before larger Phase 3 testing.

The trial was first submitted on Feb. 3, 2026, showing this is a fresh addition to the Glaukos pipeline. The last update on Feb. 24, 2026, confirms the status as “recruiting,” which signals the study is active but still in its data-gathering stage.

The primary completion and overall completion dates have not yet been reported, so investors should expect no near-term readout. This time gap matters because any value shift in GKOS tied to GLK-321 will likely come as the trial nears completion or when top-line data are released.

For investors, this update supports the view that Glaukos is broadening beyond glaucoma and corneal health into eyelid disease. If GLK-321 works, it could open a niche but growing market and complement existing players in eye surface disease such as Tarsus and others.

In the near term, the impact on GKOS stock may be modest, as the program is still early and carries typical Phase 2 risk. Still, continued pipeline progress can support sentiment and justify premium valuation multiples versus slower-moving ophthalmology peers.

Overall, the study update reinforces a long-term growth story rather than a near-term catalyst. The trial is currently recruiting and active, with more detailed information available on the ClinicalTrials portal.

To learn more about GKOS’s potential, visit the Glaukos Corp. drug pipeline page.